Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Pharmigene, Inc.

Market Cap 411M 12.98M 11.26M 10.38M 9.73M 18.17M 1.24B 18.55M 124M 47.94M 599M 48.71M 47.66M 2.08B P/E Ratio 2024
-8.68x
P/E Ratio 2025 -6.84x
Enterprise Value 980M 30.97M 26.87M 24.77M 23.21M 43.37M 2.97B 44.27M 295M 114M 1.43B 116M 114M 4.97B EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 day+8.59%
1 week-2.53%
Current month-9.10%
1 month-17.45%
3 months-21.46%
6 months-22.21%
Current year-18.28%
1 week 7
Extreme 7
8.55
1 month 7
Extreme 7
10.35
Current year 7
Extreme 7
11.85
1 year 7
Extreme 7
14.1
3 years 7
Extreme 7
25.7
5 years 7
Extreme 7
25.7
10 years 7
Extreme 7
36
Manager TitleAgeSince
Chief Executive Officer 67 2019-11-03
Chief Operating Officer 49 2019-11-03
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member 76 2020-11-23
Director/Board Member 49 2019-11-03
Chairman 67 -
Change 5-day change 1-year change 3-year change Capi.($)
+8.59%-2.53%-36.05%-62.89% 12.9M
-0.42%-3.71%+75.80%+75.34% 3.78B
-1.79%+8.31%+75.84%+130.54% 3B
-2.55%-5.00%-36.99%-41.15% 1.86B
+5.68%-2.24%+79.01%-51.29% 1.77B
-1.06%+5.87%+25.09%+183.80% 1.22B
+1.44%-9.34%-16.22%+16.32% 848M
+0.29%-29.40%+108.72% - 780M
-3.65%-0.30%+121.46%-64.63% 769M
-3.20%-3.90%-29.45%-20.93% 535M
Average +0.28%-4.93%+36.72%+18.34% 1.46B
Weighted average by Cap. -0.48%-3.77%+52.39%+49.70%

Financials

2024 2025
Net sales 117M 3.68M 3.19M 2.94M 2.76M 5.15M 352M 5.26M 35.12M 13.6M 170M 13.82M 13.52M 591M 200M 6.31M 5.48M 5.05M 4.73M 8.84M 605M 9.03M 60.25M 23.33M 291M 23.7M 23.19M 1.01B
Net income -82.86M -2.62M -2.27M -2.09M -1.96M -3.67M -251M -3.74M -24.98M -9.67M -121M -9.83M -9.61M -420M -73M -2.31M -2M -1.84M -1.73M -3.23M -221M -3.3M -22M -8.52M -106M -8.66M -8.47M -370M
Net Debt 458M 14.46M 12.55M 11.57M 10.84M 20.25M 1.38B 20.67M 138M 53.43M 667M 54.29M 53.12M 2.32B 570M 17.99M 15.61M 14.39M 13.49M 25.2M 1.72B 25.72M 172M 66.47M 830M 67.54M 66.08M 2.89B
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
26-06-11 8.090 NT$ +8.59% 44,463
26-06-10 7.450 NT$ -3.12% 106,683
26-06-09 7.690 NT$ -10.06% 84,053
26-06-08 8.550 NT$ -0.58% 26,040
26-06-05 8.600 NT$ +3.61% 32,030
  1. Stock Market
  2. Stocks
  3. 7595 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!